NOVEL PEPTIDE BASED PCSK9 VACCINE

The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases. 3. The peptide comprising the amino acid sequence of Formula (I) claim 1 , as claimed in wherein Zis selected from serine claim 1 , threonine claim 1 , valine claim 1 , alanine claim 1 , Aib claim 1 , homoserine claim 1 , O-methyl-threonine claim 1 , O-methyl-serine or O-methyl-homoserine.4. The peptide comprising the amino acid sequence of Formula (I) claim 1 , as claimed in claim 1 , wherein Zis selected from isoleucine claim 1 , leucine claim 1 , norleucine claim 1 , glycine claim 1 , alanine or Aib claim 1 , N-methyl-isoleucine or N-methyl-leucine.5. The peptide comprising amino acid sequence of Formula (I) claim 1 , as claimed in claim 1 , wherein Z3 is selected from proline claim 1 , hydroxyproline claim 1 , thiaproline claim 1 , aminoproline claim 1 , 2-thiaproline claim 1 , 3-hydroxyproline claim 1 , 3-aminoproline claim 1 , alpha-methyl-proline claim 1 , 3-fluoroproline claim 1 , 4-fluoroproline claim 1 , 1-amino-cyclopropanecarboxylic acid claim 1 , 1-amino-cyclopentanecarboxylic acid or 1-amino-cyclohexanecarboxylic acid.6. The peptide comprising amino acid sequence of Formula (I) claim 1 , as claimed in claim 1 , wherein Z4 is selected from tryptophan claim 1 , phenylalanine claim 1 , tyrosine claim 1 , 2-fluorophenylalanine claim 1 , alpha-methyl phenylalanine claim 1 , alpha-methyl-2-fluorophenylalanine claim 1 , alpha-methyl-2 claim 1 ,6-difluorophenylalanine claim 1 , 2-amino-5-phenyl-pentanoic acid claim 1 , alpha-methyl-2-amino-5-phenyl-pentanoic acid or 2′-ethyl-4′-methoxy-biphenylalanine.7. The peptide comprising amino acids sequence of Formula (I) claim 1 , as claimed in claim 1 , wherein Z5 is selected from glutamine claim 1 , histidine or aspargine.8. The peptide comprising amino acids sequence ...

SYNERGISTIC COMPOSITIONS

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) 2. The synergistic composition as claimed in claim 1 , wherein the one or more DPP IV inhibitors are selected from Sitagliptin claim 1 , Vildagliptin claim 1 , Saxagliptin claim 1 , Alogliptin and Linagliptin.3. The synergistic composition as claimed in claim 1 , wherein the one or more statins are selected from Lovastatin claim 1 , Pravastatin claim 1 , Fluvastatin claim 1 , Simvastatin claim 1 , Atorvastatin claim 1 , Rosuvastatin and Pitavastatin.4. The synergistic composition as claimed in claim 1 , wherein the one or more biguanide antihyperglycaemic agents are selected from Metformin claim 1 , Buformin or Phenformin.5. The synergistic composition as claimed in claim 1 , wherein the one or more thiazolidinediones are selected from Pioglitazone and Rosiglitazone.6. The synergistic composition as claimed in claim 1 , wherein the one or more sulphonylureas are selected from glibenclamide claim 1 , glipizide claim 1 , gliclazide claim 1 , glimepiride claim 1 , tolazamide claim 1 , tolbutamide claim 1 , acetohexamide claim 1 , carbutamide claim 1 , chlorpropamide claim 1 , glibomuride claim 1 , gliquidone claim 1 , glisentide claim 1 , glisolamide claim 1 , glisoxepide claim 1 , glyclopyamide claim 1 , glycylamide and glipentide.7. The synergistic composition as claimed in claim 1 , wherein the one or more SGLT-2 inhibitors are selected from Dapagliflozin claim 1 , Canagliflozin claim 1 , Empagliflozin claim 1 , Ertugliflozin and Ipragliflozin.8. The synergistic composition as claimed in claim 1 , wherein the one or more GLP-1 agonists are selected from Exenatide claim 1 , Liraglutide and Dulaglutide.9. (canceled)10. A method for the treatment of dyslipidemia claim 1 , hypertriglyceridemia or diabetes mellitus which comprises ...

SAROGLITAZAR MAGNESIUM FOR THE TREATMENT OF CHYLOMICRONEMIA SYNDROME

The present invention relates to the use of Saroglitazar Magnesium of formula (1), for the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. The present invention further relates to the use of a pharmaceutical composition comprising Saroglitazar Magnesium for the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. 18-. (canceled)10. A method for the reduction of postprandial triglyceride levels in patients suffering from a disease or condition which is selected from chylomicronemia syndrome claim 9 , familial chylomicronemia syndrome claim 9 , and Type V hyperlipoproteinemia claim 9 , comprising administration of a therapeutically effective amount of compound of formula (1) as claimed in to a subject in need of such treatment.11. A method to delay progression or treatment of pancreatitis in patients suffering from a disease or condition which is selected from chylomicronemia syndrome claim 9 , familial chylomicronemia syndrome claim 9 , and type V hyperlipoproteinemia claim 9 , comprising administration of a therapeutically effective amount of compound of formula (1) as claimed in to a subject in need of such treatment.12. A method to delay progression or treatment of a symptom selected from recurrent episodes of pancreatitis claim 9 , deposition of triglycerides in the skin in the form of eruptive xanthomas claim 9 , hepatosplenomegaly claim 9 , milky white triglyceride in the blood vessels in the back of the eye (lipemia retinalis) claim 9 , and mild neuro-cognitive deficits claim 9 , comprising administration of a therapeutically effective amount of compound of formula (1) as claimed in to a subject in need of such treatment.14. A method for preventing pancreatitis in a patient suffering from ...

SAROGLITAZAR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA

The present invention relates to pharmaceutical compositions containing the formula (I) for the prevention, delay of progression, or treatment of a disease or condition from hepatocellular carcinoma. The present invention further provides the composition of formula (I) useful in the prevention and treatment of hepatocellular carcinoma. 2. The method of claim 1 , wherein the pharmaceutically acceptable salt is a metal cation salt.3. The method of claim 1 , wherein the pharmaceutically acceptable salt is a metal cation salt selected from the group consisting of a sodium salt claim 1 , potassium salt claim 1 , calcium salt claim 1 , and magnesium salt.4. The method of claim 1 , wherein the pharmaceutically acceptable salt is a magnesium salt.6. The method of claim 5 , wherein M is Mg.7. A pharmaceutical composition for the treatment of Hepatocellular carcinoma comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) The compound of formula (I) or its salt thereof as claimed in ;'}b) A suitable additive agentc) a suitable stabilizer;d) optionally, with one or more pharmaceutically acceptable excipients.8. The pharmaceutical composition as claimed in wherein the suitable stabilizer is selected from antioxidants or chelating agents.9. The pharmaceutical composition as claimed in wherein the suitable antioxidants are selected from citric acid claim 8 , alpha tocopherol claim 8 , sodium sulphite claim 8 , sodium metabisulphite claim 8 , butylated hydroxy anisole (BHA) claim 8 , BHT (2 claim 8 ,6-di-tert-butyl-4-methylphenol) claim 8 , monothioglycerol claim 8 , Vitamin C (ascorbic acid).10. The pharmaceutical composition as claimed in wherein the suitable chelating agents are selected from Disodium EDTA claim 8 , citric acid and or its salts claim 8 , maleic acid claim 8 , chlorambutol claim 8 , chlorhexidine.11. The pharmaceutical composition as claimed in wherein the suitable additives are selected from sodium benzoate claim 7 , sodium hydroxide claim 7 , sodium ...

Treatment for primary biliary cholangitis

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Treatment for primary biliary cholangitis

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Treatment for primary biliary cholangitis

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.

SYNERGISTIC COMPOSITIONS

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.

Novel peptide based pcsk9 vaccine

The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.

Synergistic compositions of a ppar agonist compound of formula (ia) and one or more statin(s), or one or more dipeptidyl peptidase iv (dpp iv) inhibitor(s) or one or more biguanide antihyperglycaemic agent(s)

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions.

Synergistic compositions

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of : these novel salts and use thereof.

Synergistic compositions

Synergetic composition containing compound of formula I(a), Formula I(a) wherein M+ is magnesium and one or more therapeutic agents selected from one or more DPP-IV inhibitors or one or more biguanide antihy¬perglycemic agents or one or more statines or one or more thiazolidinediones or one or more sulfonylureas or one or more SGLT2 inhibitors or one or more GLP-1 agonists, and usage therefor diabetes treatment. Table: 31

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of : these novel salts and use thereof.

synergistic composition, method for treating dyslipidemia, hypertriglyceridemia and diabetes mellitus, use of a compound, pharmaceutical composition, process for the preparation of the pharmaceutical composition and salt

resumo “composição sinérgica, método para o tratamento de dislipidemia, hipertrigliceridemia e diabetes mellitus, uso de um composto, composição farmacêutica, processo para a preparação da composição farmacêutica e sal” a presente invenção descreve uma composição sinérgica compreendendo uma ou mais estatina(s), ou um ou mais inibidor(es) de dipeptidil-peptidase iv (dpp iv) ou um ou mais agente(s) anti-hiperglicêmico(s) biguanida e um agonista de ppar tendo a fórmula (ia) para o tratamento de diabetes, especialmente diabetes não dependente de insulina (niddm) ou diabetes tipo 2 e condições associadas com diabetes mellitus e a composições adequadas para uso em tal método. a invenção também descreve a preparação de tais composições. a presente invenção também refere-se a certos novos sais do agonista ppar tendo a fórmula (i), a processos para a preparação destes novos sais e ao uso dos mesmo. ?? ?? ?? ?? 1/1 abstract "synergistic composition, method for treating dyslipidemia, hypertriglyceridemia and diabetes mellitus, use of a compound, pharmaceutical composition, process for preparing the pharmaceutical composition and salt" the present invention describes a synergistic composition comprising one or more statin(s) , or one or more dipeptidyl peptidase iv (dpp iv) inhibitor(s) or one or more biguanide antihyperglycemic agent(s) and a ppar agonist having formula (ia) for the treatment of diabetes, especially non-insulin dependent diabetes (niddm) or type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such a method. the invention also describes the preparation of such compositions. the present invention also relates to certain new salts of the ppar agonist having formula (I), to processes for the preparation of these new salts, and to the use thereof. ?? ?? ?? ?? 1/1

Pharmaceutical combinations

Present invention relates to combination of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention provides the pharmaceutical composition of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention also provides use of the said combination or pharmaceutical composition for the treatment of inflammatory bowel disease.

Treatment for primary biliary cholangitis

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Treatment for primary biliary cholangitis

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Treatment for primary biliary cholangitis

The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.